Article Sidebar
Views pdf: 46
THE EFFICACY OF DOCETAXEL PLUS TRASTUZUMAB AS THE FIRST-LINE IN PATIENTS WITH RECURRENT OR METASTATIC HER2-POSITIVE BREAST CANCER AT K HOSPITAL
Main Article Content
Abstract
Objectives: Describe of clinical and paraclinical characteristics as well as evaluate the efficacy of doccetaxel plus trastuzumab as the first-line in patients with recurrent or metastatic HER2-positive breast cancer. Patients and methods: A retrospective and prospective descriptive study on 56 patients diagnosed with HER2-positive metastatic or recurrent breast cancer at K Hospital from January 2015 to October 2022. Result: The mean age was 53.1±14.3 years. The majority of patients relapsed after 3 years of treatment, accounting for 64.3%. The most common metastatic sites were liver, bone and lung, respectively, accounting for 44.6%, 37.5% and 26.7%. The overall response rate of the regimen was 64.3%. The complete response rate was 7.1%. 26.8% of the patients were stable, 8.9% of patients were progressive, The progression-free survival time is 7 months, the overall survival time is 41 months. Conclusion: Doccetaxel plus trastuzumab as the first-line in patients with recurrent or metastatic HER2-positive breast cancer is effective in high response rates, the patient is well tolerated. Thisregimens may be more widely used in clinical practice.
Article Details
Keywords
Recurrent or metastatic breast cancer, HER2-positive.
References
2. Maaren MC van, Munck L de, Strobbe LJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019;144(2):263-272. doi:10.1002/ijc.31914
3. Sato N, Sano M, Tabei T, et al: Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, Phase-II study. Breast Cancer 13, 166–171 (2006).
4. Raab G, Brugger W, Harbeck N, et al: Multicenter randomized Phase II study of docetaxel (Doc) given q3w vs. q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC). Breast Cancer Res. Treat. 76, S114 (2002)
5. Tedesco KL, Thor AD, Johnson DH, et al: Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional Phase II trial. J. Clin. Oncol. 22, 1071–1077 (2004).
6. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol Off J Am Soc Clin Oncol. 2005; 23(19): 4265-4274. doi:10.1200/JCO. 2005.04.173
7. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20): 3271-3277. doi:10.1200/JCO. 2009.25.9820
8. Vũ Thị Trang. Đánh giá kết quả hóa trị vinorelbine kết hợp trastuzumab trong ung thư vú di căn có HER2 dương tính tại Bệnh viện K. Luận văn thạc sĩ, 2019.
9. Pienkowski T, Forbes J, Valero V, et al: BCIRG 007: Randomized Phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). Ann. Oncol. 17, (2006)
10. Robert N, Leyland-Jones B, Asmar L, et al: Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 24, 2786–2792, (2006).